Identified in the mid-1990s, CCR5 (a protein expressed on the surface of leukocytes) elicited a frenzy in the HIV medical and scientific communities. Its role as a gateway receptor for HIV infection of T cells sparked high hopes for some kind of prevention or therapy against the deadly virus. This book explores in very minute detail how the gene coding for the CCR5 protein has been handled in contemporary ‘bio-capitalism’, i.e. ‘the product of biotechnology, which sees biological entities, such as genes, as part of scientific projects of profit-making and project-seeking’ (p. 22). After the first chapter, used as a scientific and historical introduction, subsequent chapters form a ‘genealogy’ of the gene, ‘including lineages of biocapitalism, the science of chemokines and HIV/AIDS, the Human Genome Project and the HAPMAP, intellectual property law, big and small pharma, personal genomics companies, and race’ (p. 24). Intellectual-property issues get the lion's share: Chapters 2 to 5 are focused on the patents regarding CCR5, and how these patents have been handled by the United States Patent Office and its European and Japanese counterparts. The CCR5 gene and protein (and their functions) have been patented in the US, though the patents granted have been subject to severe criticisms. According to several companies that appealed against the patents granted in Europe and the US, there was no invention, nor utility, in the broad patent applications. In fact, the book explores some of the complex legal issues related to intellectual property of the genetic sequence, its products and the technological derivatives based on the detection and use of the sequence or the proteins it produces (i.e. diagnostic tests and potential therapies). In these chapters, Jackson uses the CCR5 gene almost as an excuse to explore decades of patent policies in the US, Europe and Japan. As a result, we see that biotech and biocapitalism in the US enjoyed a long spell of friendly courts with regard to gene patenting and accepting very broad claims by the patent applicants. In the other contexts, patent offices as well as governments have created a less welcoming environment for biotech patents (especially when dealing with human genes and broad protection claims). This attitude is slowly changing in the US, as the recent BRCA1/2 controversy showed, while in Europe broad patent claims on genes and their products have always been under closer scrutiny. Stricter rules for defining invention and utility claims mark a different approach to life sciences and biotech – Sheila Jasanoff is explicitly quoted, as she noted in several works how moral values may affect biotech in different cultural contexts. The US differs from Europe and Japan in adopting a more ‘capitalist’ approach to biotech, though in Europe major oppositions on broad patent coverage on CCR5 came from market competitors; that is, full capitalistic actors. The technological fallout of CCR5 (in diagnostics and in therapeutics) is explored in Chapter 6, where the outcomes of intellectual-property policies are also explored, with regard to the licensing of tests and drugs in several countries. The author warns here of the likely ‘exclusion of many people from treatment’ (p. 120) for economic reasons, and suggests – building on past experiences – that extreme measures such as compulsory licensing ‘might be the way forward’ (p. 120). The remaining two chapters take up different issues: here the ‘genealogy’ of the gene is taken at face value, focusing on genetic research in human population diversity. Chapter 7 explores how hypotheses of the selective value of different CCR5 alleles (in particular, the Δ32 allele is linked to resistance to HIV) have been linked to the history of human populations, before such narratives were refuted by the development of genomic tools able to spot the signatures of natural selection. Several disciplines share an interest in tracing the evolution of human populations, so that different perspectives have been used to categorize human genetic variation and to link ethnic differences – ‘races’ – to easy-to-spot genetic markers. Yet ‘race’ is a very slippery concept: even when used naively – and many scientists did so – it has a historical load impossible to forget. ‘Race’ calls for an interdisciplinary effort in order to understand how biology and history of human populations interacted, creating cultural separations as well as favouring certain genetic traits. The last chapter adds a new flavour to the usual discourse about race: its exploitation as a marketing instrument and a commodity. In recent years, several drugs or therapeutic options have been offered to specific groups identified on a ‘racial’ basis – such as African Americans, though often no clear biological traits have been related to such specificities. Biocapitalism here is at work with feelings of inclusion and exclusion (race simultaneously acts on both), with individually tailored therapies, with categories of patients, and finally with the very definition of race not as a concept but as a practice (for example in clinical trials). In this context, private companies (large and small) need to interact with other stakeholders – patients, regulators – often following the lead of the other actors in the scene. Politics is far from helpless in creating the conditions for a fair use of biomedical technologies.
The book is dense and sometimes very complex (it also includes a glossary to explain biomedical terms). Key concepts are pretty clear, though, and repeatedly explained: CCR5 is used as a perspective to observe the conditions for the development and functioning of biocapitalism, and how different communities define and use the gene in the biocapitalistic context. The book appeals to many students – scientists included – for its multifaceted approach covers extensively the multidimensional form of contemporary life sciences. Though it is sometimes naive in its critical approach to biocapitalism (see, for example, the closing lines of Chapter 4, in which patent wars fought by biotech companies are used to state that biocapitalism is not a united front), the book is extremely stimulating. Its historical perspective on the present is compelling and appealing, providing tools – and further questions to ask – to understand contemporary society.
